Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Antigen Presenting Cells01:22

Antigen Presenting Cells

3.0K
The immune system is a complex network of cells and molecules that protects the body from foreign invaders. T cells, a type of white blood cell, play a crucial role in this process. They recognize and attack foreign substances, such as pathogens, that enter the body.
T cells require the help of antigen-presenting cells (APCs), which process foreign antigens into smaller fragments that can be recognized by T cells. These APCs are highly specialized cells that efficiently internalize antigens...
3.0K
Cancer Vaccines01:30

Cancer Vaccines

960
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
960

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correlation between recognition of autologous tumor organoids by tumor-infiltrating lymphocytes from metastatic epithelial cancers and clinical response.

Journal for immunotherapy of cancer·2026
Same author

Vaccination rescues dysfunctional T cell therapy by amplifying rare stem-like antitumor CD8<sup>+</sup> T cells.

Research square·2026
Same author

Identification of HLA class II-restricted T cell receptors against shared PIK3CA mutations in patients with epithelial cancers.

Cancer immunology, immunotherapy : CII·2025
Same author

Selective expansion of T-cell receptor engineered T cells with increased stem-like phenotypes using neoantigen stimulation.

Journal for immunotherapy of cancer·2025
Same author

The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee.

Journal for immunotherapy of cancer·2025
Same author

Survival after anti-CD19 CAR T-cell therapy for B-cell non-Hodgkin lymphoma and CLL with 10 years of follow-up.

Blood advances·2025

Related Experiment Video

Updated: Jan 15, 2026

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles
09:28

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles

Published on: November 17, 2018

12.0K

Facts and Hopes for Neoantigen-Enriched TIL.

Siqi C Brough1, Kristen L Skonieczny1, Stav Leibou1

  • 1Surgery Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|October 15, 2025
PubMed
Summary

Tumor-infiltrating lymphocyte (TIL) immunotherapy, approved for melanoma, shows promise for epithelial cancers. Ongoing research aims to enhance TIL selection strategies for improved solid tumor treatment efficacy.

More Related Videos

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.7K
Peptide:MHC Tetramer-based Enrichment of Epitope-specific T cells
13:58

Peptide:MHC Tetramer-based Enrichment of Epitope-specific T cells

Published on: October 22, 2012

18.6K

Related Experiment Videos

Last Updated: Jan 15, 2026

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles
09:28

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles

Published on: November 17, 2018

12.0K
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.7K
Peptide:MHC Tetramer-based Enrichment of Epitope-specific T cells
13:58

Peptide:MHC Tetramer-based Enrichment of Epitope-specific T cells

Published on: October 22, 2012

18.6K

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Adoptive transfer of tumor-infiltrating lymphocytes (TIL) immunotherapy was FDA-approved for metastatic melanoma in 2024.
  • Translating TIL therapy to epithelial cancers relies on understanding tumor-T cell interactions from melanoma studies.
  • Identification of neoantigens and neoantigen-reactive TIL is crucial for this translation.

Purpose of the Study:

  • To review the current status and future directions of TIL immunotherapy for solid tumors.
  • To highlight the importance of neoantigen identification and TIL selection strategies.
  • To discuss the challenges and opportunities in expanding TIL therapy beyond melanoma.

Main Methods:

  • Review of recent advancements in TIL immunotherapy research and clinical trials.
  • Analysis of studies focusing on neoantigen discovery and TIL repertoire.
  • Examination of laboratory techniques for TIL selection and enrichment.

Main Results:

  • TIL immunotherapy has shown efficacy in checkpoint-refractory metastatic melanoma.
  • Laboratory-guided TIL selection has resulted in modest tumor regression.
  • New strategies for enriching TIL are under development to improve clinical outcomes.

Conclusions:

  • TIL immunotherapy holds significant potential for treating various solid tumors.
  • Enhanced strategies for selecting and enriching TIL are needed to improve efficacy.
  • Further research into tumor-T cell interactions is vital for advancing TIL therapy.